SCHEMBL5151899

SCHEMBL5151899

COC(=O)c1ccc(N)cc1NC(C)=O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 4/20 0.60
SMN1; SMN2 Q16637 2/20 0.51
KDM4E B2RXH2 9/20 0.48
ALDH1A1 P00352 9/20 0.48
HPGD P15428 4/20 0.47
HSD17B10 Q99714 3/20 0.47
ATM Q13315 3/20 0.47
MAPT P10636 2/20 0.47
CASP1 P29466 2/20 0.47
CASP7 P55210 2/20 0.47
GLA P06280 2/20 0.47
MAPK1 P28482 1/20 0.47
ABL1 P00519 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KMT2A Q03164 1/20 0.44
CDK1 P06493 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5627215 0.87 GAA (0.56) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL31196721 0.87 GAA (0.56) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL973761 0.83 ALDH1A1 (0.52) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL13088436 0.81 KDM4E (0.69) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL12021288 0.81 SMN1; SMN2 (0.53) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL30487008 0.81 KDM4E (0.69) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL9510448 0.80 GAA (0.53) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL5928755 0.80 ABL1 (0.58) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL3990612 0.80 ABCG2 (0.56) GAASMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL7149329 0.80 KDM4E (0.54) GAASMN1; SMN2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110498751-B Imprinted template molecule and preparation method and application thereof 南京医科大学 2021-10-08 CN disclosed
US-20070054909-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 US disclosed
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 US disclosed
EP-1189612-A4 VLA-4 INHIBITOR COMPOUNDS DAIICHI SEIYAKU CO (JP) 2005-02-16 EP disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 US disclosed
US-6756378-B2 BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) PHARMACOPEIA DRUG DISCOVERY, INC. 2004-06-29 US disclosed
US-20030078249-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-04-24 US disclosed
EP-1189612-A1 VLA-4 INHIBITOR COMPOUNDS Daiichi Pharmaceutical Co., Ltd. (JP) 2002-03-27 EP disclosed
WO-2001000206-A1 VLA-4 INHIBITOR COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078249-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGA4 GAA 1709/4885SMN1; SMN2 4151/4885KDM4E 695/4885
US-20070054909-A1 VLA-4 inhibitor compounds VCAM1, ITGB4, ICAM1 GAA 1575/4885SMN1; SMN2 4245/4885KDM4E 409/4885
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 GAA 1727/4885SMN1; SMN2 4213/4885KDM4E 669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.